tesamorelin_10mg

Tesamorelin 10mg

10mg
€73,75
Skip to product information
tesamorelin_10mg

Tesamorelin 10mg

Express delivery in 1-3 business days.

Each peptide comes with bacteriostatic water.

€73,75
Packaging
✅ Quality analysis - Janoshik

Our peptides are produced under strict quality and control standards. Each product is supplied in lyophilized form, which ensures stability and prevents deterioration during transport, even under unfavorable conditions. We test every batch.

❌ Why we don't offer solutions

We do not offer pre-made aqueous solutions because the peptide molecules in them are significantly less stable. The presence of water accelerates processes such as hydrolysis, oxidation, and aggregation, which leads to a gradual loss of activity and efficacy of the peptides.

Even under optimal conditions, the shelf life of peptide solutions is limited to about 4 weeks. Unlike aqueous solutions, the lyophilized form preserves the structure and biological activity of peptides for a long period - up to 24 months under refrigerated conditions and up to 4 months at room temperature.

❄️ Proper storage

When stored in a refrigerator at a temperature of 2°C – 8°C, the shelf life is up to 24 months. If kept at room temperature, stability is maintained for approximately 3–4 months.

After reconstitution, the peptides are in a more unstable form and should be stored in a refrigerator for up to 4 weeks.

📦 Delivery

At PurePeptide, we provide fast and secure delivery through Econt Express. Orders are processed within 1–3 business days and delivered to an Econt office or personal address with cash on delivery.

Standard delivery time is 1–3 days, with most shipments arriving within 1–2 days. After dispatch, you will receive a confirmation email. You will receive an SMS notification when the shipment arrives at the Econt office.

With us, you can be sure that your order will arrive quickly, reliably, and in excellent condition.

📖 Dissolution

  1. Work in a clean environment and use sterile supplies.
  2. Chill the peptide and bacteriostatic water in the refrigerator.
  3. Using a sterile syringe, draw the required volume of bacteriostatic water.
  4. Aim the needle at the inner wall of the lyophilized substance vial and slowly add the bacteriostatic water.
  5. Gently swirl the vial until the powder is completely dissolved.
  6. Store the reconstituted solution in a refrigerator at 2–8°C. Its shelf life under these conditions is 4 weeks.

What is Tesamorelin?

Tesamorelin is a synthetic peptide analog of GHRH (Growth Hormone-Releasing Hormone), created to stimulate endogenous growth hormone release by interacting with GHRH receptors in the pituitary gland. Unlike direct growth hormone administration, Tesamorelin acts by activating natural pituitary GH secretion.

In scientific literature, Tesamorelin has been primarily discussed in relation to the regulation of the GH/IGF-1 axis, visceral adipose tissue, lipid metabolism, and metabolic risk. Its best-documented clinical data are in HIV-associated lipodystrophy, where it has been studied for its effect on abdominal visceral adipose tissue.

One of the most frequently discussed aspects of Tesamorelin is its ability to stimulate pulsatile growth hormone release, which secondarily leads to an increase in IGF-1. In research and clinical models, this has been associated with changes in body composition, lipolysis, fat distribution, and certain indicators of metabolic function.

Observations with Tesamorelin

  • GH/IGF-1 axis – discussed in relation to stimulating endogenous growth hormone release and increasing IGF-1.
  • Visceral adipose tissue – in clinical studies, an effect on the reduction of abdominal visceral fat has been described in specific study populations.
  • Metabolic processes – studied in relation to lipid profile, energy balance, and fat metabolism regulation.
  • Hepatic steatosis – in some scientific literature, Tesamorelin has been studied in HIV-associated fatty liver disease and changes in liver fat.
  • Body composition – discussed in relation to fat tissue distribution, waist circumference, and changes in the visceral fat compartment.
  • Cellular and hormonal regulation – studied as a model for the relationship between GHRH signaling, GH secretion, IGF-1, and metabolic adaptation.

Scientific Data

In clinical studies, Tesamorelin has been described as a synthetic GHRH analog that stimulates pituitary growth hormone secretion. The increase in GH leads to a secondary increase in IGF-1, which is used as an important marker for the activity of the GH axis.

The most strongly documented data are related to HIV-associated lipodystrophy. In these models, Tesamorelin has been studied for its ability to reduce visceral adipose tissue without acting as a direct replacement for growth hormone. Some studies have described changes in waist circumference, body composition, and certain lipid parameters.

Additional publications discuss Tesamorelin in HIV-associated non-alcoholic fatty liver disease. In this context, the peptide has been studied in relation to liver fat, metabolic regulation, inflammatory processes, and potential influence on fibrotic progression.

Potential effects discussed in scientific literature

  • Stimulation of endogenous growth hormone secretion
  • Increase in IGF-1 as a marker for GH axis activity
  • Reduction of visceral adipose tissue in certain study populations
  • Influence on body composition and abdominal fat distribution
  • Changes in lipid profile and metabolic indicators
  • Research interest in HIV-associated lipodystrophy
  • Potential link with hepatic steatosis and fatty infiltration
  • Involvement in the regulation of energy balance and lipolysis

Administration and Dosage

In scientific and clinical literature, Tesamorelin is described with subcutaneous administration within controlled protocols. The most commonly discussed clinical regimens involve once-daily administration, and this data is provided for informational purposes only and does not constitute a recommendation for use.

Example concentrations for 5 mg / 2 ml solution:

0.2 ml = 0.5 mg

0.4 ml = 1 mg

0.6 ml = 1.5 mg

0.8 ml = 2 mg

Example concentrations for 10 mg / 2 ml solution:

0.1 ml = 0.5 mg

0.2 ml = 1 mg

0.3 ml = 1.5 mg

0.4 ml = 2 mg

Possible Side Effects

In clinical and research data, Tesamorelin is generally described as well-tolerated, but reactions related to both the injection site and the activation of the GH/IGF-1 axis may be observed. Reported reactions include:

  • redness, itching, or discomfort at the injection site
  • muscle or joint pain
  • fluid retention
  • headache
  • numbness or tingling sensation in the extremities
  • increase in IGF-1 in sensitive individuals
  • changes in glucose metabolism in certain at-risk groups

Due to its influence on the GH/IGF-1 axis, in a clinical context, parameters such as IGF-1, glucose, HbA1c, and overall metabolic status are monitored. The data should not be automatically applied to healthy individuals or other populations outside of the specific study groups.

The information is summarized based on available scientific publications and is for educational purposes only. It should not be used for diagnosis, treatment, or prevention of diseases.

See also